FCCC LOGO Faculty Publications
Awan MJ , Gittleman H , Barnholtz-Sloan J , Machtay M , Nguyen-Tan PF , Rosenthal DI , Schultz C , Huth BJ , Thorstad WL , Frank SJ , Kim H , Foote RL , Lango MN , Shenouda G , Suntharalingam M , Harris J , Zhang Q , Le QT , Yao M
Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522
Oral Oncol. 2021 Feb 25;116 :105241
Back to previous list
OBJECTIVES: To develop nomograms predicting overall survival (OS), freedom from locoregional recurrence (FFLR), and freedom from distant metastasis (FFDM) for patients receiving chemoradiation for laryngeal squamous cell carcinoma (LSCC). MATERIAL AND METHODS: Clinical and treatment data for patients with LSCC enrolled on NRG Oncology/RTOG 0129 and 0522 were extracted from the RTOG database. The dataset was partitioned into 70% training and 30% independent validation datasets. Significant predictors of OS, FFLR, and FFDM were obtained using univariate analysis on the training dataset. Nomograms were built using multivariate analysis with four a priori variables (age, gender, T-stage, and N-stage) and significant predictors from the univariate analyses. These nomograms were internally and externally validated using c-statistics (c) on the training and validation datasets, respectively. RESULTS: The OS nomogram included age, gender, T stage, N stage, and number of cisplatin cycles. The FFLR nomogram included age, gender, T-stage, N-stage, and time-equivalent biologically effective dose. The FFDM nomogram included age, gender, N-stage, and number of cisplatin cycles. Internal validation of the OS nomogram, FFLR nomogram, and FFDM nomogram yielded c = 0.66, c = 0.66 and c = 0.73, respectively. External validation of these nomograms yielded c = 0.59, c = 0.70, and c = 0.73, respectively. Using nomogram score cutoffs, three risk groups were separated for each outcome. CONCLUSIONS: We have developed and validated easy-to-use nomograms for LSCC outcomes using prospective cooperative group trial data.
1879-0593 Awan, Musaddiq J Gittleman, Haley Barnholtz-Sloan, Jill Machtay, Mitchell Nguyen-Tan, Phuc Felix Rosenthal, David I Schultz, Christopher Huth, Bradley J Thorstad, Wade L Frank, Steven J Kim, Harold Foote, Robert L Lango, Miriam N Shenouda, George Suntharalingam, Mohan Harris, Jonathan Zhang, Qiang Le, Quynh-Thu Yao, Min NRG Oncology Group Journal Article England Oral Oncol. 2021 Feb 25;116:105241. doi: 10.1016/j.oraloncology.2021.105241.